NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, the biotechnology subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that the company has signed an extension of its letter of intent with emerging biotech innovator Amarantus BioSciences (OTCBB: AMBS). Amarantus is on the verge of delivering startling new breakthroughs in the diagnosis and treatment of neurological disorders from Parkinson’s disease to Traumatic Brain Injury (TBI). Amarantus owns the rights to a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis as well as the license to a groundbreaking diagnostic platform called NuroPro that allows neurologists to accurately diagnose and track the progression of Parkinson’s disease in patients.
